Mekonos is using its novel cell-engineering platform to create a future where personalized medicine is accessible to all. By combining cutting-edge semiconductor technology, microfluidics, and proprietary surface chemistry, Mekonos' platform enables the ex vivo delivery of any molecular cargo to any cell. Mekonos' non-viral approach offers unprecedented viability, precision, and control in molecular payload delivery - unlocking the full potential of gene editing for cell engineering. Mekonos is well positioned to support cell engineering applications across all aspects of therapeutic development - biomanufacturing, cell therapies, drug screening, and disease modeling for regenerative medicine development. Mekonos offers collaborators a scalable solution to seamlessly move from R&D to manufacturing and opens the doors to a new world of possibilities, including complex genetic modifications and challenging cell types currently inaccessible with conventional delivery technologies.